Skip to main content

Vistagen Therapeutics, Inc.

VTGN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001411685

No open-market purchases or sales by Vistagen Therapeutics, Inc. insiders were filed in the last 90 days; 48 institutions reported holding it in 13F filings for Q2 2026, worth $2.54M in total; no superinvestor holds it.

Q3 2024 vs. Q2 2024

How the institutions holding Vistagen Therapeutics, Inc. changed between Q2 2024 and Q3 2024.

All holders in Q3 2024All holders in Q2 2024

13F holders of VTGN: Q2 2024 compared with Q3 2024
MeasureQ2 2024Of which not filed for Q3 2024Q3 2024Change
Holders43147+5
Shares16.3M402.7K15.3M−674.7K (−4.2%)
Value$56.3M$1.40M$45.3M−$9.60M (−17.5%)

1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.

New holders (8)

Institutions that held Vistagen Therapeutics, Inc. at the end of Q3 2024 but not at the end of Q2 2024.

Institutions new to VTGN in Q3 2024
InstitutionSharesValue% of portfolio
BlackRock, Inc.412,129$1.24M0.00%
ADAR1 Capital Management, LLC163,078$490.9K0.08%
Valence8 US LP34,376$103.5K0.05%
Millennium Management LLC25,337$76.3K0.00%
HighTower Advisors, LLC20,828$64.0K0.00%
Kestra Advisory Services, LLC20,033$60.3K0.00%
Jane Street Group, LLC19,659$59.2K0.00%
Caption Management, LLC4,460$13.4K0.00%

Sold out (3)

Institutions that held Vistagen Therapeutics, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.

Institutions that sold out of VTGN in Q3 2024
InstitutionShares, Q2 2024Value, Q2 2024
Armistice Capital, LLC300,000$1.04M
Barclays PLC19,261$67.0K
Qube Research & Technologies Ltd492$1.71K

Not filed for Q3 2024 yet (1)

Institutions that held Vistagen Therapeutics, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding VTGN in Q2 2024 that haven't filed for Q3 2024
InstitutionShares, Q2 2024Value, Q2 2024
BlackRock Inc.402,747$1.40M